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The role of host genetic factors 
in respiratory tract infectious 
diseases: systematic review, meta-
analyses and field synopsis
Inga Patarčić1,*, Andrea Gelemanović1,*, Mirna Kirin1, Ivana Kolčić1, Evropi Theodoratou2, 
Kenneth J. Baillie3,4, Menno D. de Jong5, Igor Rudan2, Harry Campbell2 & Ozren Polašek1,2
Host genetic factors have frequently been implicated in respiratory infectious diseases, often with 
inconsistent results in replication studies. We identified 386 studies from the total of 24,823 studies 
identified in a systematic search of four bibliographic databases. We performed meta-analyses of 
studies on tuberculosis, influenza, respiratory syncytial virus, SARS-Coronavirus and pneumonia. 
One single-nucleotide polymorphism from IL4 gene was significant for pooled respiratory infections 
(rs2070874; 1.66 [1.29–2.14]). We also detected an association of TLR2 gene with tuberculosis 
(rs5743708; 3.19 [2.03–5.02]). Subset analyses identified CCL2 as an additional risk factor for 
tuberculosis (rs1024611; OR = 0.79 [0.72–0.88]). The IL4-TLR2-CCL2 axis could be a highly interesting 
target for translation towards clinical use. However, this conclusion is based on low credibility of 
evidence - almost 95% of all identified studies had strong risk of bias or confounding. Future studies 
must build upon larger-scale collaborations, but also strictly adhere to the highest evidence-based 
principles in study design, in order to reduce research waste and provide clinically translatable 
evidence.
Infectious diseases are characterized by a number of unique features - they rely on a single agent as a 
cause, they can be transmitted from one person to another and cause epidemics, and they have had a 
strong impact on human evolution1,2. In addition, infectious diseases can be eradicated, but also new 
ones may emerge, creating a dynamic stage for human-infection interplay3.
Even the most basic insight into the infectious disease occurrence and outcomes suggests strong 
inter-individual differences, commonly attributable to the host genetics profile. Adoption, twin and her-
itability studies provided the first line of evidence that corroborate this4,5, leading to an increased interest 
in understanding of genetic background of infectious disease in the last decade of the 20th century6,7. As 
a result, over 4,000 candidate-gene studies were published between 2001 and 2010, often focusing on 
respiratory infections and especially on tuberculosis8. However, these studies often provided conflicting 
results9,10. Some of the problems of such studies included low study power, high risk of publication bias, 
differences in study designs, especially cases and controls recruitment schemes, which altogether led to 
often bias and confounding, genotyping inaccuracies, and substantial problems in phenotype definition, 
especially in the case of tuberculosis11–13. The entire field was plagued by very unfavourable effect-to-bias 
ratios, a situation in which the magnitude of bias exceeds that of the sought effect14. Not even the use of 
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hypothesis-free approaches, like genome-wide association studies15, managed to spark a progress of the 
field, indicated as a lack of replication of results from such studies10,16–18. Unfortunately, insights derived 
from the fields of clinical infectology, microbiology, immunology, epidemiology, as well as clinical, evo-
lutionary and population genetics remained largely isolated from one another19–21, preventing systematic 
understanding of the entire field.
The interest in host factors associated with respiratory infectious diseases stems from their ability 
to cause epidemics and pandemics. The infamous Spanish influenza of 1918 has been implicated as 
the largest ever recorded pandemic, causing an estimated 25–100 millions of deaths22,23. On the other 
hand, tuberculosis is an example of highly adaptive pathogen, which managed to coevolve with humans, 
possibly as far as the initial waves of human migrations out of Africa24–26. The 2013 estimates suggested 
that 9 million of people suffered from it globally, with 1.5 million of attributable deaths annually and 
possibly as much as a third of all living humans being latent carriers27. Pneumonia remains to be one of 
the main childhood mortality causes, with an estimated 120 million episodes and 1.3 million of lethal 
outcomes globally28. Similarly, respiratory syncytial virus (RSV) is attributable for 33.8 million episodes 
of newly diagnosed acute lower respiratory infections worldwide in children under 5 years, with at least 
3.4 million episodes of severe cases requiring hospital admission29. Finally, SARS-Coronavirus outbreak 
in 2003 was an example of how quickly a novel respiratory pathogen can spread on a global scale30,31.
Understanding the host genetic side could be an invaluable tool in clinical medicine, especially because 
susceptibility to an infectious agent lies at least partly hidden or masked in inborn errors or immune 
response32,33. This renders infectious diseases a high-ranking research priority, having in mind the mobil-
ity of modern human population and the ever changing pathogen nature. Therefore, the aim of this study 
was to provide a field synopsis and systematic review with meta-analyses of host genetic susceptibility to 
respiratory infectious diseases. A special focus was set on the comparative analysis of different clinical 
presentations and pathogens, aiming to increase the understanding of both shared and specific disease 
pathways that could have been identified on the basis of previously published candidate gene studies. We 
also provide a critical overview of the entire field and generalized framework for improvement of future 
studies in infect-omics - application of genomics, proteomics metabolomics or other omics technologies 
in understanding of the infectious disease development, progression and outcome.
Results
A total of 2,209 data points were extracted from 386 studies. The majority of data addressed tuberculosis 
(1,417 data points; 64.1%), followed by RSV (285; 12.9%), SARS-Coronavirus (198; 9.0%) and influenza 
(84; 3.8%), pneumonia (172; 7.8%), while the rest were on other respiratory infections such as otitis 
media and bronchitis (53; 2.4%). There were 274 different genes in the data, with most frequent results 
for TNFA (123; 5.6%), IL10 (117; 5.3%) and SLC11A1 (92; 4.2%). A total of 949 distinctive markers were 
recorded in the database, but only 89 met the inclusion criteria of at least four data points available 
per marker, and were used in the subsequent meta-analysis. Out of 1,963 data points with all three CSI 
score domains scored, only 107 data points (5.5%) had credible CSI score (having only A or B grades), 
while the remaining 94.5% of data points had at least one C grade and were thus considered to have 
weak credibility (Fig. 1). Disease-specific CSI profiles indicated better quality of studies on pneumonia, 
influenza and tuberculosis, while CSI scores were lower in case of SARS-Coronavirus and respiratory 
syncytial virus (RSV) (Supplementary Figure 1).
Among investigated data points, a total of 1,952 were attributable to infectious disease susceptibility 
(88.4%), 172 to disease severity (by comparing severe vs. mild disease cases; 7.8%) and 38 to mortality 
(1.7%), while the remaining studies were based on comparison of tuberculosis skin-test positivity results 
with controls. We performed a total of 515 disease susceptibility meta-analysis in all four genetic models, 
with a total of 86 nominally significant results (Supplementary Tables 3–6). However, only two genes 
retained noteworthiness for the mid/low BFDP level (Table  1). The first one was IL4 gene, for pooled 
result in allelic model (rs2070874; OR = 0.79, 95% CI [0.70–0.89]; Supplementary Figure 2), and pooled 
result in recessive model (rs2070874; 1.66 [1.29–2.14]; Supplementary Figure 3). The second one was 
TLR2 gene for tuberculosis in allelic model (rs5743708; 3.19 [2.03–5.02]; Supplementary Figure 4). We 
did not detect strong traces of publication bias in all meta-analyses (plots available in RISEdb website).
Subset analysis of methodologically better studies (with controls of known exposure to the pathogen) 
revealed five nominally significant results, with a single noteworthy result (Supplementary Table 7) - 
CCL2 gene (rs1024611; OR = 0.79 [0.72–0.88]; Table  1). There were no significant results for severity 
models (Supplementary Table 7), while we did not perform mortality meta-analysis due to lack of at least 
four published studies for any marker.
We identified a total of 19 family and linkage-based studies, which were not included in the 
meta-analysis due to methodological restraints. These studies covered either broad genome regions on 
chromosomes 3–7, 10–12, 15, 17, 19, 20, X, or specific genes such as SLC11A1 (NRAMP1), IL8, CCR5, 
IL12RB1, SP-A, SP-D, SLC22A4, SCL22A5, RAD50, FBOX11 and EVI1 gene (Supplementary Table 8). 
We also identified 11 GWAS studies; seven were on tuberculosis, three on otitis media and one on 
influenza. Two genome-wide significant results were recorded for tuberculosis, belonging to WT1 gene 
and ASAP1 gene (Supplementary Table 9). We also identified 54 published meta-analyses, of which 
the majority addressed genetic susceptibility to tuberculosis. However, these meta-analyses investigated 
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infection susceptibility in much wider set of clinical appearances, often with manifestations not restricted 
to respiratory tract, and were thus not directly comparable to this study.
Discussion
This is the first extensive, systematic review and meta-analysis of all published studies that were address-
ing host genetic factors implicated in five common respiratory tract infectious diseases - tuberculosis, 
influenza, respiratory syncytial virus (RSV), SARS-Coronavirus and pneumonia. Until now, majority of 
published studies and meta-analyses were based on one pathogen - one polymorphism approach, focus-
ing on pathogen susceptibility. Only a handful of published studies compared different respiratory tract 
diseases. In addition, majority of previously published meta-analyses addressed tuberculosis, and none 
was found for SARS-Coronavirus, RSV and influenza. Therefore, by developing this entire resource we 
Figure 1. Quality score assessment, based on confounding, selection bias and information bias risk, 
based on 1,963 data points from RISE database (only data points with all three CSI domain scores were 
analysed here). 
Gene
Disease; genetic 
model rs code
Heterozy-
gote
Risk 
allele N studies
N cases 
(alleles)
N Controls 
(alleles)
OR  
[95% CI] P
I2  
[95% CI]
Venice 
score
BFDP 
(med/low)
BFDP 
(very low)
IL4 Pooled result; allelic rs2070874 CT T 6 2908 6422
0.79 
[0.70-
0.89]
7.68E-
05
0.06 
[0.00–
0.76]
BAC 0.063 0.779
IL4 Pooled result; recessive rs2070874 CT T 5 1059 2210
1.66 
[1.29–
2.14]
8.68E-
05
0.00 
[0.00–
0.39]
BAC 0.128 0.886
TLR2 Tuberculosis; allelic rs5743708 AG A 6 3262 3124
3.19 
[2.03–
5.02]
4.91E-
07
0.00 
[0.00–
0.63]
BAC 0.087 0.834
CCL2
Tuberculosis; hete-
rozygote advantage, in 
exposed controls
rs1024611 AG G 4 3066 3556
0.79 
[0.72–
0.88]
1.26E-
05
0.00 
[0.00–
0.83]
BAC 0.014 0.426
Table 1. Significant and noteworthy results of meta-analyses (the entire set of results is available in 
Supplementary Tables 3, 4 ,5 and 6). Abbreviations used: TBC – tuberculosis, BFDP - Bayesian false-
discovery probability.
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enabled not only disease-specific analyses, but also analyses of the shared (pooled) infectious disease 
mechanisms in the respiratory system - all in the stringent evidence-based manner.
In total, we found two results that withstood multiple testing correction: IL4 in pooled model and 
TLR2 for tuberculosis. Additionally, we established a role of CCL2 in tuberculosis, by including only a 
subset of methodologically better studies, where controls were of known exposure.
IL4 has previously been described to have a pivotal role in shaping the nature of immune response, by 
promoting and stimulating both T-cell and B-cell differentiation34. It provides a balance between Th1 and 
Th2 response, and therefore alteration of its function may substantially affect immune response34. Most 
commonly reported such alteration is associated with increased risk of atopy and allergies35. Furthermore, 
IL4 seems to have a direct role in infectious disease outcome - IL4-deficient mice were more susceptible 
to Legionella pneumophila and had increased mortality rates compared to controls36. This was the single 
result that was significant in pooled analyses, and marginal in disease-specific meta-analyses. This reflects 
the need for studies with more statistical power, but also suggests that this is one of the most likely trans-
latable results towards clinical application across the wider spectrum of respiratory infectious diseases.
TLR2 is a member of large family of genes involved in pathogen recognition and signalling cascade 
of innate immune response37. Previous studies have suggested its role in the susceptibility to tuberculo-
sis38–40, but also in other bacteria such as Mycoplasma, Mycobacterium, Neisseria and other Gram-positive 
bacteria41. Interestingly, despite being closely linked to CD14 mechanisms37, the results of this study 
showed that CD14 had no association with tuberculosis, while TLR2 had a very strong result, with odds 
ratio of 3.2. This finding could point towards a specific role of TLR2 in tuberculosis, with weaker asso-
ciation or even lack of such association in other elements of the immune response. Interestingly, TLR2 
effects seem to be very context-specific, as the absence of TLR2 in knock-out mice did not affect their 
clinical outcomes, nor did it seem to have a role in secondary infections42. This suggests that the exact 
mechanisms of its function are still elusive, and that more focused studies are needed, taking into account 
the exact pathophysiological processes in patients with tuberculosis.
CCL2 gene has been associated with diseases that include monocytic infiltrations43, migration and 
retention of monocytes in particular locations44, and consequently in granuloma formation45–47. As such, 
its role in tuberculosis has been described previously48,49, with notable ethnic-specific differences50. In 
this study, CCL2 gene was significant only in a subset analysis, where studies with exclusively exposed 
controls were sub-selected. This clearly demonstrates that methodological improvements can have pos-
itive effect on gene discovery. Very complex genetic architecture of infectious diseases development, 
coupled with errors and omissions in primary study designs, might explain this accumulation of large 
amount of poorly usable evidence. Therefore, one of the main conclusions of this study is that the best 
way forward is through improvement of primary studies and reduction of research waste.
An overview of family and linkage-based studies suggested frequent differences in study designs, 
marked by dissimilarities in phenotype definitions, marker types and analytic approaches. Nevertheless, 
the association of tuberculosis with SLC11A1 was replicated in two studies51,52, with a notable exception in 
the third one (Supplementary Table 8)53. There was no overlap of candidate-gene studies and GWAS10,54, 
thus prohibiting comparative analysis. All GWAS studies provided a two significant and replicated result, 
located in an intergenic region near WT1 gene (rs2057178)16,55 and ASAP1 gene (rs10956514)56. Other 
reported signals were not replicated in independent cohorts (Supplementary Table 9). This is likely a con-
sequence of largely underpowered study designs (with sample sizes rarely exceeding 1,000 cases or con-
trols), but more importantly methodological problems that were carried over from the candidate-gene 
study designs. Up-scaling the study in terms of genetic resolution (from single marker or just a few 
markers to thousands and hundreds of thousands of markers in GWAS), increase in the sample size 
and use of more advanced analytic methods will likely not provide a substantial step forward before we 
manage to overcome methodological and study design limitations. In addition, we are faced with a high 
level of genetic complexity57, and duality between rare, Mendelian variants, which may confer complete 
immunity, but have very low prevalence in a population58, or common variants, which usually have much 
lower explained variance, and therefore have a limited capacity for clinical intervention. The principal 
step forward is to create larger-scale collaborations and enable data sharing, built upon the common 
framework for analysis, based on aligned protocols, larger-scale harmonizing and collaborative efforts59.
The results of this study fit into previously implied mechanisms of respiratory infections, where 
CCL7-CCL2-CCR2 axis was described to have a critical role in IL4 production and immune response 
and regulation in both fungal60 and viral infections61, as well as atherosclerosis62 and tumours63. Despite 
differences described from in vitro and in vivo studies64, this could be the most interesting translatable 
mechanism towards clinical medicine. In addition, WT1 gene from GWAS studies16,55, implied in sus-
ceptibility to tuberculosis, has been described to be under control of CCL2, which seems to be having 
target-responsive cytocidal activity on WT1-specific mechanisms65. This mechanism could, at least partly, 
explain the relationship between some infections and tumours66. However, to clarify their relationship 
and provide a step forward, we must firstly be able to derive much better evidence from primary studies.
Primary study design was one of the main barriers for the further field development, with almost 
95% of all extracted data points assessed as having strong risk of bias or confounding. The improvements 
must be embodied into evidence-based principles, and have to be undertaken in almost all domains of 
the field, including better clinical definitions and phenotyping, improved controls selection and diag-
nostics, appropriate statistical analysis, favourable study design, the use of novel molecular technologies 
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and better reporting with larger sample sizes obtained through consortia development. Firstly, we need 
to improve phenotype definitions and criteria for diagnosis, especially in case of latent tuberculosis13,67. 
The use of proxy and extreme phenotypes, which was seen in HIV, with exposed uninfected subjects, 
long-term non-progressors, fast progressors and elite controllers68–70, might also provide an interesting 
step forward71. It was very common for authors to use the term “healthy” controls, but almost univer-
sally used dissimilar diagnostic process for classification of cases and controls. Thus, selection of controls 
and diagnostics process must be fundamentally improved and harmonized (Supplementary Table 10). 
A substantial effort must go towards inclusion of controls that were exposed to a pathogen, which is 
necessary for the disease development (but may not be sufficient). Data analysis must also be improved, 
by adhering to the best practices, including the use and report of odds ratios and confidence intervals 
as measures of association, and multiple testing correction72. Improvements can be made in the study 
design, where availability of finely phenotyped life-long cohorts and biobanks provides an opportunity 
to use this data in an understanding of life-long risk of developing respiratory infectious disease, such as 
tuberculosis. The use of novel molecular technologies, various omics, and their application to infectious 
disease development, progression and outcome (infect-omics) presents an unprecedented opportunity in 
this field73. However, these must be based on evidence-based, always include estimates of repeatability 
and focus on replication efforts in an unlinked population. Lastly, we must substantially improve results 
reporting. This refers to the structured manuscript preparation, reporting of all relevant information and 
manuscript preparation against a given set of criteria like STREGA74, STROBE-ME75 or STREIS, where 
appropriate76. This also extends to the need to develop individual-data public repositories and creation 
of large-scale consortia that share common standard-operating procedures, similarly to these in chronic 
disease genetic epidemiology. We do not neglect the proposed finer scale analyses of various population 
subsets67, but we consider improvements in study design to have much stronger potential impact. All 
these suggestions are applicable not only for genomics, but also for any type of infect–omics studies, 
defined as application of various -omics technologies in understanding of the infectious disease devel-
opment, progression and outcome. In addition, we need to start developing framework of systematic 
reviews, where we need to compare disease-specific genes and pathways to disease-specific genes, as the 
final outcome, clinical disease, might be attributable to different sets of genes that make a person more 
susceptible to e.g. pneumonia regardless on the pathogen that is causing it. Only by comparing such 
complementary results and insights will we be able to better understand and harness this information 
in clinical care.
These results must be viewed in light of numerous limitations. We reviewed a very diverse field with 
no unified reporting scheme, suggesting that the search might have missed some relevant articles and 
data sources. In order to accommodate for this problem we performed extensive search supplemented 
by hand-search procedure described in Materials and methods section. Existence of wider-scale unpub-
lished data and occasionally our inability to obtain raw data present another possible source of bias. This 
study also suffers from the limited input, due to exclusion of HLA and KIR markers, haplotypes and 
complete omission of any information on pathogen, thus providing rather limited insight into the field 
and possibly missing out some of the key element for more in-depth understanding77. Most of these lim-
itations have very negative impact on effect-to-bias ratio, where bias may be several orders of magnitude 
greater than the size effects. We attempted to contrast this by the use of the stringent analytic approach in 
an evidence-based manner, including multiple testing correction, careful application of inclusion criteria 
and quality assessment scoring, coupled with use of random-effect meta-analysis. The study also suffers 
from inability to adjust the analysis for basic covariates, such as age, sex and comorbidity information. 
We also used a novel score for quality assessment that was developed within this study and was not 
validated before. We thus provided basic agreement indices, but wider use of this score would require 
an in-depth reliability assessment and validation. If we turn back to biological processes, earlier primary 
studies ignored microbiomes, while some novel studies are suggesting that lungs are not sterile78,79 and 
that respiratory tract microbiomes could have strong modifying effect on health and disease mechanisms. 
Despite all these limitations, we attempted to provide a field synopsis, supplemented by a generalized 
framework that could be useful not only for respiratory infectious disease genetics, but can be extended 
to all infectious diseases. However, these results are just the first step it an attempt to provide a reflection 
of just one side of the infectious disease story – the host. Only by combining the host genomics (and 
other –omics) information with pathogen –omics will we be able to truly advance this field and enable 
the development of personalized infectious disease medicine.
Materials and Methods
Protocol and registration. The review strategy and details were registered prospectively in 
PROSPERO as the record 2014:CRD42014009072.
Eligibility criteria. We undertook an extensive and systematic search of all published studies related 
to host genetics implicated in development or outcome of respiratory tract infectious diseases. Instead 
of focusing on a single-disease approach, we aimed at delivering systematic evidence on all respiratory 
infections, including cases where a syndrome phenotype was reported, such as pneumonia, without the 
specific pathogen information.
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Information sources. We used three bibliographic databases; PubMed (http://www.ncbi.nlm.nih.gov/
pubmed), Web of Science (http://wok.mimas.ac.uk) and Scopus (http://www.scopus.com). We also per-
formed an additional search of the HuGe Literature Finder (http://www.hugenavigator.net), to identify 
articles that might have been missed in PubMed.
Search. Two of the joint first authors performed the search and study selection, which was supervised 
by the last author. The last author also resolved any discrepancies in scoring system or data extraction 
process. The search was performed on May 06, 2014, with an update performed on August 25, 2015. 
After duplicates removal, the search yielded a total of 24,823 articles. All identified articles were firstly 
checked for inclusion by reading the Title and Abstract. This led to identification and exclusion of a 
total of 23,677 studies. The remaining 881 articles were supplemented by hand search of their references, 
producing an additional set of 265 articles. In total, we used a set of 1,146 articles that were read in full 
and screened against inclusion criteria (Supplementary Figure 5).
Study selection. The study selection process was based on iterative steps. Firstly, the studies needed 
to report the number of cases and controls for every analysed genotype. Therefore, we initially excluded 
all of the family-based and linkage studies, as well as genome-wide association (GWAS) studies from 
this meta-analysis, due to inability to obtain complete set of GWAS results in the appropriate format. 
However, we retained these studies and provided their qualitative summary, in order to develop an inclu-
sive field synopsis. Secondly, studies had to be based on biallelic single-nucleotide polymorphisms (SNP) 
or biallelic insertion-deletion marker type. Studies based on other marker types (including microsatellites 
or short tandem repeats), or those that reported aggregated haplotypes were excluded. We also excluded 
all studies that reported exclusively gene expression profiles without relevant genotyping information. We 
then limited the review to studies that were published during or after the year 2000 and were written in 
English language. Despite similarity of disease patterns and mechanisms, we excluded all animal and all 
in vitro studies and focused on susceptibility in previously healthy subjects. We also excluded studies that 
reported: any outcome in previously affected patients (either as a part of immunodeficiency syndromes 
or with any form of disease such as asthma, HIV/AIDS or other comorbidities; where reported), fungal 
infections (due to also very prevalent comorbidities), nosocomial infections (such as ventilator-related 
or hospital-acquired pneumonia), exclusively pathogen genotypes or host-pathogen interactions. Studies 
that reported non-respiratory infection sites (such as extra-pulmonary tuberculosis, meningitis or inva-
sive pneumococcal disease) were also excluded, as the focus of this study was on respiratory infectious 
diseases. Lastly, we excluded all studies that were obviously reporting previously published results or 
were re-using the cases that has already been used elsewhere (when we managed to identify this), in 
order to remove redundant data or publications from meta-analysis. To ensure a systematic source of 
information, we additionally checked studies which provided insufficient information. A total of 142 
e-mails were sent to authors of studies which we classified as having reported insufficient information, 
and asked for clarifications or raw data sharing. We also contacted all authors of identified GWAS stud-
ies to share their results. This entire process results in a total of 10 responses (4 rejections, 2 responses 
that did not meet the inclusion criteria and 4 cases of clarifications or shared raw data, which are listed 
in the Acknowledgements). In total, we used 386 articles in the data extraction process (Supplementary 
Figure 5).
Data collection process and data items. A total of 48 pieces of information were extracted for 
every study (available in the on-line RISEdb – Respiratory Infection SuscEptibility database, available at 
http://www.prepare-europe.eu/risedb). All the data were extracted and entered into a database by two 
authors, and checked by the third, in order to ensure data integrity. Each identified study was indexed 
with a unique identification code (RISEdb ID). Some studies provided more than one data point (which 
corresponds to one marker - one study data entry), and were consequently represented with more than 
one data entry in our database. In all instances the data were extracted in the raw format as genotype 
counts, or were calculated from the reported percentages and total sample sizes where number of cases 
and controls was not available. When more cases or control groups were available in one study, we either 
pooled them or retained multiple data points from the same study, especially in case of having discovery 
and replication datasets. In addition, all data points were classified according to the underlying research 
question into three categories: studies that investigated infectious disease susceptibility, disease severity 
or disease mortality. In addition, we defined a subset of methodologically better studies, where controls 
were of known exposure to the pathogen.
Risk of bias in individual studies. We developed a novel score for purposes of risk of bias assess-
ment. As the methodological design defines, a study may be prone to three main domains of errors and 
bias – confounding, selection bias and information bias. These three domains were the basis for the score 
development, which was entitled Confounding-Selection-Information bias score - CSI (Supplementary 
Table 2). The elements of the score were developed on the basis of several previous studies80 and assess-
ment scores, including Venice criteria for assessing cumulative epidemiologic evidence in genetic asso-
ciations81, Newcastle-Ottawa case-control scale82, Cochrane risk of bias tool83, and previously established 
quality scores in genetic epidemiology84. Neither of these tools provided a good fit for the risk of bias 
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assessment in observational studies in genetic epidemiology, and we therefore took elements of previous 
scales and derived a new one. In line with Venice criteria, we scored all three domains in three grades 
of credibility: high - graded as A; intermediate - B or weak – C. This scheme provided estimates ranging 
from the best AAA to worst CCC score, which was applied to every data point in RISE database (and 
not for the meta-analysis results, as the Venice criteria is intended to). Since information bias can affect 
several aspects of the study, we also divided information bias risk domain in three separate sub-scores, 
relating to cases and controls selection and genotyping procedures, with the worst of all three defining 
the overall information bias risk. All CSI scoring was done independently by two authors, and all discrep-
ancies were settled by an agreement or input from a third author (there were 313 or 14.2% data points 
with initially dissimilar grades, providing good agreement with kappa coefficient of 0.717 and standard 
error for kappa of 0.011).
As an additional quality control check, we re-calculated Hardy-Weinberg test for every control set 
included in the analysis, using a two tailed chi-square test or an exact test, when appropriate. Those 
data points that failed HWE test at the level of P < 0.05 were downgraded to C in the CSI score (there 
were 225 out of 2,209, or 10.2% of all analysed data points that failed HWE), in order to reflect possible 
methodological limitations of failed HWE (which indicates both the risk for selection and/or informa-
tion bias). Where cases from a single study were classified as moderate or severe, we did not determine 
Selection domain of CSI score (a total of 246 data points). In such instances we assigned 0 to selection 
bias risk, as there was no selection process involved, and second-stage analysis was performed
Summary measures and synthesis of results. In the first step of meta-analysis we calculated 
all odds ratios anew from raw data, in order to provide a common analytic framework and reduce 
possible differences in data analysis. In order to better understand the genetic architecture underlying 
gene-disease association, we performed analyses using four separate genetic models: allelic, dominant, 
recessive and heterozygote advantage. Model selection was based on commonly used allelic model, two 
additional models that assume different inheritance effects (dominant and recessive), followed by the 
heterozygote advantage, as previous studies reported such results85–87. All calculations were therefore 
based on allele counts, rather than exact cases and controls counts. We compared the results of different 
models, in an attempt to provide broader insight into genetic architecture.
Minor allele frequencies in Homo sapiens Short Variation (GRCh38) data set were obtained from 
Ensembl Biomart on 08.12.201488. We then performed a series of meta-analyses for all SNPs where 
four or more data points were available for a single SNP. We used random effects meta-analysis, assum-
ing differences in designs and ethnic composition of individual studies. We also calculated fixed-effects 
model, in order to compare the results. We used I2 statistics and corresponding confidence intervals as 
a measure of heterogeneity.
In order to account for multiple testing as a result of numerous meta-analyses and different genetic 
models being performed, we used Bayesian false-discovery probability (BFDP)72. It was calculated for 
nominally significant results only, with a threshold of 0.2, using an online free version of the BFDP cal-
culator (http://faculty.washington.edu/jonno/BFDP.xls). In addition, we calculated BFDP using two prior 
probabilities, with medium/low prior level (0.05 to E-03), consistent with a candidate gene; and very low 
prior level (E-04 to E-06), consistent with a random SNP. The advantage of this approach over the com-
monly used corrections is that it is not dependent on the number of tests performed, as it relies on odds 
ratios and confidence intervals for calculation. In addition, it provides conceptual improvement over 
the similar methods, such as false-positive report probability (FPRP)89. Due to substantial requirements 
for appropriate use of publication bias analysis methods90, we only examined publication bias visually.
All analyses were performed in R, version 2.15.391. Meta-analysis was performed with package meta 
3.2–0 and metabin, forest and funnel functions92. Hardy-Weinberg equilibrium testing was performed 
in HardyWeinberg_1.5.2 package93, with HWExactMat or HWChisqMat functions, based on the cell 
expected frequencies.
Risk of bias across studies. For purpose of meta-analysis credibility assessment, we used Venice cri-
teria81, in all instances of nominally significant results. Study power was assessed on the basis of sample 
sizes (with sample sizes of up to a 1,000 graded as C, 1,001–10,000 graded as B, and over 10,001 graded 
as A). Heterogeneity was based on I2 statistics (graded as A in case of 0–25%, B in case of 26–50% and 
C in case of I2 being over 50% ), while the third score domain was fixed as C (weak credibility), due to 
very prevalent risk of bias in primary studies.
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